Every Form 4 that Corcept Therapeutics Inc. (CORT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CORT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CORT filings page.
Corcept Therapeutics’ Chief Development Officer William Guyer exercised stock options and sold shares on May 5, 2026. He exercised options to acquire 20,000 shares of common stock at $21.65 per share, then sold 20,000 shares in an open-market transaction at a weighted average price of $51.83 per share, with actual prices ranging from $51.60 to $52.05. Following these transactions, he directly holds 2,231 common shares, which include 224 and 498 shares underlying unvested restricted stock awards that each vest in full one year after their respective grant dates if conditions are met. He also holds 170,000 fully exercisable stock options with a $21.65 exercise price expiring on September 1, 2031. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 27, 2024.
Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff reported an open-market sale of 40,000 shares of Common Stock on May 1, 2026 at a weighted average price of $50.0965 per share. The transaction was executed indirectly through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02, over which he has voting power pursuant to voting agreements.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2024. Following this transaction, the trust holds 2,878,326 shares of Corcept Therapeutics Common Stock, for which Belanoff disclaims beneficial ownership except to the extent of his pecuniary interest.
Corcept Therapeutics director James N. Wilson, through an entity associated with him, reported a bona fide gift of 2,000 shares of Corcept common stock on April 22, 2026. The gift was made by the James N. Wilson and Pamela D. Wilson Trust and is classified under transaction code G, indicating a non-market transfer with no sale proceeds.
After the gift, that trust still held 1,095,532 shares of Corcept common stock indirectly. The filing also lists additional indirect holdings, including 200,000 shares in the Pamela D. Wilson 2025 Grantor Retained Annuity Trust, 200,000 shares in the James N. Wilson 2025 Grantor Retained Annuity Trust, and 901,067 shares held by James and Pamela Wilson Family Partners. A footnote states that Wilson has voting power over certain entities’ shares under voting agreements and disclaims beneficial ownership except to the extent of his pecuniary interest.
Corcept Therapeutics Chief Development Officer William Guyer exercised stock options for 20,000 shares of common stock at an exercise price of $21.65 per share and then sold 20,000 shares. The sale was at a weighted average price of $40.97 per share, with individual trade prices ranging from $40.85 to $41.30.
The transactions occurred on April 7, 2026 and were made under a Rule 10b5-1 trading plan adopted on November 27, 2024. Following the sale, Guyer directly holds 2,231 shares of common stock, including 224 shares underlying restricted stock awards granted on December 1, 2025 and 498 shares underlying restricted stock awards granted on March 2, 2026, which will vest in full on the one-year anniversaries of their grant dates if specified conditions are met. The option exercised was fully exercisable and was scheduled to expire on September 1, 2031.
Corcept Therapeutics director James N. Wilson reported a bona fide gift of 5,000 shares of Common Stock on April 6, 2026. The transfer was made by the James N. Wilson and Pamela D. Wilson Trust and is classified as a non-market, no‑price gift disposition.
Following the gift, the trust held 1,097,532 shares indirectly, while the James and Pamela Wilson Family Partners entity held 901,067 shares, and each of the 2025 Grantor Retained Annuity Trusts held 200,000 shares. Wilson has voting power under voting agreements but disclaims beneficial ownership beyond his pecuniary interest.
Corcept Therapeutics’ Chief Executive Officer Joseph K. Belanoff reported an open-market sale of 26,198 shares of common stock at a weighted average price of $50.0735 per share. The trade was executed indirectly through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust.
The sale occurred under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2024. Following this transaction, the trust-related holdings reported for Belanoff total 2,918,326 shares of Corcept Therapeutics common stock.
Corcept Therapeutics director James N. Wilson reported a bona fide gift of 4,000 shares of Common Stock. The gift was made at no stated price by the James N. Wilson and Pamela D. Wilson Trust, an entity through which he holds shares indirectly. Following this transaction, that trust holds 1,102,532 shares, with additional indirect holdings reported through a family partnership and two 2025 grantor retained annuity trusts.
Corcept Therapeutics Chief Development Officer William Guyer exercised stock options for 11,767 shares of common stock at $21.65 per share and on the same day sold 11,767 shares at a weighted average price of $36.01 per share. The sale prices ranged from $35.97 to $36.24 per share and was carried out under a Rule 10b5-1 trading plan adopted on November 27, 2024. Following these transactions, he directly holds 2,231 shares of common stock, plus 224 shares and 498 shares underlying unvested restricted stock awards that are scheduled to vest in full on the one-year anniversaries of their December 1, 2025 and March 2, 2026 grant dates, respectively, subject to specified conditions. The option exercised for 11,767 shares was fully exercisable before this transaction.
Corcept Therapeutics director Leonard G. Baker Jr. reported buying a total of 100,000 shares of Common Stock in open-market transactions on March 17, 2026. The purchases were split between 75,782 shares at a weighted average price of $33.0022 and 24,218 shares at a weighted average price of $33.5633, with actual trade prices ranging from $32.43 to $33.68.
Following these purchases, Baker directly holds 1,146,631 Corcept shares. He also has indirect interests in 3,308,303 shares held by a limited partnership and 1,095,262 shares held by a trust, while disclaiming beneficial ownership except to the extent of his pecuniary interests.
Director James N. Wilson, through the James N. Wilson and Pamela D. Wilson Trust, made a bona fide gift of 28,000 shares of Corcept Therapeutics common stock on March 13, 2026, with no cash changing hands. The filing shows that, after this gift, the trust held 1,106,532 shares, while the James and Pamela Wilson Family Partners entity held 901,067 shares, and each of two 2025 Grantor Retained Annuity Trusts held 200,000 shares. Wilson has voting power over the trust and family partnership holdings but disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.
Corcept Therapeutics director David L. Mahoney reported a series of routine equity transactions. He exercised stock options covering 30,000 shares of Common Stock at $5.86 per share, converting a derivative position into directly held shares.
To cover the exercise price through a net, cashless exercise, 5,469 shares were withheld at a value of $32.15 per share, which is a tax/payment mechanism rather than an open-market sale. The remaining 24,531 shares were transferred as a bona fide gift to the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust and are now reported as indirectly owned.
After these transactions, Mahoney reports 1,237,145 shares of Common Stock held indirectly through the family trust and an additional 46,147 shares held indirectly through The Black Dog Private Foundation. The filing shows no open-market purchases or sales of Corcept Therapeutics stock.
Corcept Therapeutics’ Chief Development Officer William Guyer exercised 8,233 stock options and sold the resulting shares. On March 4, 2026, he exercised options for 8,233 shares of common stock at an exercise price of $21.65 per share and then sold 8,233 shares in the open market at a weighted average price of $35.9949 per share, with individual sale prices ranging from $35.97 to $36.05. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 27, 2024. After these transactions, Guyer held 2,231 shares of common stock directly, as well as options and restricted stock awards, including 224 and 498 shares underlying unvested restricted stock awards that vest on the one-year anniversaries of their respective grant dates, subject to specified conditions.
Corcept Therapeutics officer Joseph Douglas Lyon reported routine equity compensation activity in the company’s common stock. On March 2, 2026, he acquired 398 shares in a grant or award and another 398 shares tied to a purchase plan, with the price based on that day’s closing price.
On March 3, 2026, 89 shares were disposed of through share withholding to cover tax obligations related to vesting restricted stock units, rather than an open-market sale. Following these transactions, he directly holds 11,230 shares, including unvested restricted stock awards that generally vest one year after their grant dates if required conditions are met.
Corcept Therapeutics executive Sean Maduck reported equity award activity and related tax withholding. On March 2, 2026, he acquired two grants of common stock totaling 908 shares, including 454 purchase-plan shares priced under a company purchase plan and 454 shares granted at no cost as an award. On March 3, 2026, 110 shares were withheld by Corcept at a price of $35.97 per share to cover tax obligations tied to vesting restricted stock units, leaving 8,977 common shares held directly.
The filing also lists indirect ownership stakes through several entities, including the Sean and Molly Maduck Living Trust, MMM 2025, LLC, two SNM Grantor Retained Annuity Trusts, and Duckhill Capital, LLC. Maduck disclaims beneficial ownership of Duckhill Capital, LLC shares beyond his pecuniary interest.
Corcept Therapeutics’ Chief Business Officer Gary Charles Robb reported routine equity compensation activity in the company’s common stock. On March 2, 2026, he acquired 499 shares at $35.97 per share under a purchase plan established pursuant to the 2024 Incentive Award Plan, and received an additional 499-share restricted stock award at no stated cost. These awards include unvested restricted stock that will fully vest on the one-year anniversary of each grant if specified service and ownership conditions are met.
On March 3, 2026, 121 shares were disposed of at $35.97 per share to satisfy tax withholding obligations tied to vesting restricted stock units, meaning the shares were withheld by the company rather than sold in the open market. After these transactions, Robb directly held 79,503 shares and indirectly oversaw 11,571 shares held in a custodial account for a child under the Uniform Transfers to Minors Act.
Corcept Therapeutics Chief Development Officer William Guyer reported two stock acquisitions. On March 2, 2026, he acquired 498 shares of common stock at $35.97 per share under a purchase plan and received an additional 498 restricted shares at no cost. After these transactions, he directly owned 2,231 shares, including unvested restricted stock awards that vest after one year if specified service and ownership conditions are met.
Corcept Therapeutics Chief Financial Officer Atabak Mokari reported a mix of share awards and tax withholding transactions in company stock. On March 2, 2026, he acquired 397 shares of common stock in one grant/award transaction at $35.97 per share and another 397-share grant at a stated price of $0.00 per share.
On March 3, 2026, 96 shares were disposed of in a tax-withholding transaction at $35.97 per share to cover obligations tied to vesting restricted stock units. Following these transactions, he directly owned 15,257 shares of common stock, including unvested restricted stock awards subject to future vesting conditions.
Lyon Joseph Douglas reported acquisition or exercise transactions in this Form 4 filing.
Corcept Therapeutics reported that officer Joseph Douglas Lyon received a grant of stock options covering 140,000 shares of the company’s stock. The options were awarded as a form of equity compensation and are held directly by Lyon.
According to the terms, the options begin vesting on February 27, 2026 and will vest in equal monthly installments over a four-year period, as long as Lyon continues providing service through each vesting date. This structure is designed to spread the potential ownership benefit over time and align it with ongoing service.
BELANOFF JOSEPH K reported acquisition or exercise transactions in this Form 4 filing.
Corcept Therapeutics reported that Chief Executive Officer Joseph K. Belanoff received a grant of stock options covering 460,000 shares on February 27, 2026. These options give him the right to buy company stock and are structured as long-term incentive compensation.
The options vest in equal installments on each monthly anniversary of February 27, 2026, over a four-year period, and each vesting installment is conditioned on his continued service through the applicable vesting date.
Corcept Therapeutics' Chief Financial Officer receives a new stock option grant. On February 27, 2026, CFO Atabak Mokari was granted stock options covering 140,000 shares of Corcept Therapeutics common stock at an exercise price of $0.00 per share, recorded as a direct ownership position.
The options vest in equal monthly installments over four years, starting from the monthly anniversary of February 27, 2026, and require the executive’s continued service through each vesting date. After this grant, the reported derivative holdings from this award total 140,000 options.
Corcept Therapeutics reported that officer Sean Maduck received a grant of stock options covering 140,000 shares of the company’s stock. The award was recorded as an acquisition of derivative securities at no cash cost on the grant date.
According to the terms, these options vest in equal installments on each monthly anniversary of February 27, 2026 over a four-year period, and vesting requires Mr. Maduck’s continued service through each vesting date. Following this grant, he is shown as holding stock options for 140,000 shares directly.
Corcept Therapeutics reported that Chief Scientific Officer Hazel Hunt received a grant of stock options. The award covers 140,000 stock options with a stated exercise price of $0.00 per share, reflecting a compensatory equity grant rather than an open-market purchase.
These options begin vesting from February 27, 2026 and will vest in equal installments on each monthly anniversary of that date over a four-year period. Vesting is conditioned on Hunt’s continued service through each vesting date, tying the award to long-term employment and performance.
Robb Gary Charles reported acquisition or exercise transactions in this Form 4 filing.
Corcept Therapeutics granted Chief Business Officer Gary Charles Robb stock options covering 140,000 shares on February 27, 2026. These options vest in equal monthly installments over four years starting on February 27, 2026, subject to his continued service through each vesting date.
Corcept Therapeutics reported that Chief Development Officer William Guyer received a grant of stock options to acquire 140,000 shares of the company’s stock. The options were awarded at an exercise price of $0.00 per share, reflecting a compensatory award rather than an open-market purchase.
The options begin vesting on February 27, 2026 and will vest in equal monthly installments over a four-year period, contingent on Guyer’s continued service through each vesting date. Following this award, he holds stock options covering 140,000 shares directly.
Corcept Therapeutics director James N. Wilson reported several equity moves involving stock options and trust-related holdings. He exercised stock options for 100,000 shares of common stock at an exercise price of $3.88 per share through a derivative conversion.
Of the resulting shares, 10,636 shares of common stock were disposed of to cover the exercise price or tax liability at a price of $36.48 per share in a tax-withholding transaction. He then made a bona fide gift of 89,364 shares of common stock, transferring them without consideration to the James N. Wilson and Pamela D. Wilson Trust.
The filing shows 1,134,532 shares of common stock held indirectly by the James N. Wilson and Pamela D. Wilson Trust, 901,067 shares held indirectly by James and Pamela Wilson Family Partners, and 200,000 shares each held indirectly by the James N. Wilson 2025 Grantor Retained Annuity Trust and the Pamela D. Wilson 2025 Grantor Retained Annuity Trust. Wilson has voting power over the trust and partnership shares pursuant to voting agreements and disclaims beneficial ownership except to the extent of his pecuniary interest.
Corcept Therapeutics officer Sean Maduck, President of Corcept Endocrinology, reported several indirect ownership changes in Corcept common stock dated January 8, 2026. Entities associated with him made bona fide gifts of 20,570 and 34,000 shares held indirectly through the Sean and Molly Maduck Living Trust and a related trust, each at a stated price of $0.00 per share. Corresponding entries show 20,570 shares held by MMM 2025, LLC and 34,000 shares held by the SNM 2026 Grantor Retained Annuity Trust, both entities associated with Maduck. He also reports 8,179 shares held directly, which include unvested restricted stock awards scheduled to vest one year after their respective grant dates if service conditions are met, plus additional indirect holdings through another grantor retained annuity trust and Duckhill Capital, LLC.
Corcept Therapeutics Chief Scientific Officer Hazel Hunt reported an option exercise and related share withholding. On February 9, 2026, Hunt exercised stock options for 150,000 shares of common stock at an exercise price of $3.88 per share, converting a stock option that was fully exercisable and scheduled to expire on February 26, 2026.
To cover the option exercise price and associated tax withholding in a net (cashless) transaction, 77,968 common shares were withheld at a price of $41.31 per share. After these transactions, Hunt directly held 255,437 shares of Corcept Therapeutics common stock.
Corcept Therapeutics Chief Development Officer William Guyer reported an option exercise and share sale. On February 3, 2026, he exercised a stock option for 20,000 shares of common stock at $21.65 per share and then sold 20,000 shares at a weighted average price of $40.8667 under a prearranged Rule 10b5-1 trading plan adopted on November 27, 2024. After these transactions, he directly held 1,235 shares of common stock and 230,000 stock options that are fully exercisable.
Corcept Therapeutics director Leonard G. Baker Jr. reported multiple stock option exercises on January 27, 2026, converting options into blocks of 25,000–30,000 common shares at exercise prices between $5.86 and $15.15. These transactions are coded as option exercises, not open-market sales.
After the reported transactions, a trust for which he serves as trustee holds 1,095,262 Corcept common shares indirectly, and a limited partnership associated with a trust of which he is trustee holds 3,308,303 shares. He also directly holds 1,046,631 shares. The filing states he disclaims beneficial ownership in the trust and partnership shares except for his pecuniary interest.
Corcept Therapeutics Chief Development Officer William Guyer reported option exercises and share sales in company stock. On January 6, 2026, he exercised a stock option for 20,000 shares of common stock at an exercise price of $21.65 per share and then sold 20,000 shares of common stock at a weighted average price of $35.1828 per share. The filing notes that the sale prices ranged from $34.96 to $35.50 per share. These transactions were made under a Rule 10b5-1 trading plan adopted on November 27, 2024. After the transactions, Guyer directly held 1,235 shares of common stock and 250,000 stock options that are reported as fully exercisable.
Corcept Therapeutics director James N. Wilson reported several internal movements of Corcept common stock among family-related entities on December 12, 2025. A family trust disposed of 400,000 shares as a gift at a reported price of $0.00 per share, leaving 1,045,168 shares held indirectly through the James N. Wilson and Pamela D. Wilson Trust.
Two 2025 grantor retained annuity trusts each received 200,000 shares without consideration and are reported as indirectly holding 200,000 shares apiece. The report also lists 901,067 shares of Corcept common stock held indirectly through James and Pamela Wilson Family Partners, over which Wilson has voting power pursuant to voting agreements while disclaiming beneficial ownership except to the extent of his pecuniary interest.
Corcept Therapeutics (CORT) Chief Development Officer William Guyer reported transactions on 11/05/2025. He exercised 20,000 stock options at $21.65 and sold a total of 20,000 shares in multiple trades, including 6,536 shares at a weighted average of $74.7489, 13,164 shares at $75.6365, and 300 shares at $76.28. Following these trades, he directly owned 5,287 shares and held 290,000 derivative securities (options) afterward. The transactions were made under a Rule 10b5-1 plan adopted on November 27, 2024.
Corcept Therapeutics (CORT) insider transaction: Chief Accounting & Technology Officer Joseph Douglas Lyon exercised 5,000 stock options at $13.56 per share on 11/03/2025 and sold 5,000 common shares the same day at a weighted average price of $73.6489. The filing notes sale prices ranged from $73.47 to $73.945 per share.
Following these transactions, he beneficially owned 10,277 shares directly. The filing also notes unvested restricted stock awards granted on 12/02/2024 (215 shares), 03/03/2025 (216 shares), 06/02/2025 (749 shares), and 09/02/2025 (200 shares), which vest 100% on the one-year anniversary of each grant, subject to conditions. The option exercised was fully exercisable and relates to a grant expiring 02/07/2030, with 16,571 derivative securities beneficially owned afterward.
The sale was made pursuant to a Rule 10b5-1 trading plan adopted on 08/30/2024.
Corcept Therapeutics (CORT) CEO and director Joseph K. Belanoff reported open‑market sales totaling 40,000 shares pursuant to a Rule 10b5‑1 trading plan adopted on November 26, 2024.
The trades occurred on November 3, 2025 (11,218 shares at $74.0786) and November 5, 2025 (14,355 at $74.196; 10,837 at $75.1372; 3,590 at $75.9777). Following these sales, 2,741,370 shares were beneficially owned indirectly through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02.
He has voting power over the trust shares pursuant to voting agreements and disclaims beneficial ownership except to the extent of his pecuniary interest.
Corcept Therapeutics (CORT) officer Sean Maduck exercised stock options for 20,000 shares at $8.27 on 11/03/2025, then sold 20,000 shares at a weighted average price of $73.9908. The sale was made pursuant to a Rule 10b5-1 plan adopted on 09/05/2024.
After these transactions, he directly holds 7,904 shares and 261,986 stock options. Indirect holdings are 59,717 shares via the Sean and Molly Maduck Living Trust, 40,000 shares via the SNM 2025 GRAT, and 10,000 shares via Duckhill Capital, LLC.
Corcept Therapeutics (CORT) director reports option exercise and sale. On 10/10/2025, the reporting person exercised 2,200 stock options at $14.08 per share and sold 2,200 shares at $87.54, both reported as direct holdings. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 1, 2024.
Following these transactions, common stock directly held was 0 shares. The filer reports 1,100 derivative securities (stock options) remaining directly owned, which are fully exercisable and carry an expiration date of 08/20/2028.
Insider transactions by Chief Development Officer William Guyer show simultaneous option exercise and stock sales dated 10/07/2025. Mr. Guyer exercised 20,000 stock options at an exercise price of $21.65 per share, immediately acquiring 20,000 shares. The same day he sold 20,000 shares under a Rule 10b5-1 plan for a weighted average sale price of $89.9391 per share (range $89.85–$90.18). After these transactions his reported beneficial ownership is 25,287 shares of common stock and he holds 310,000 shares underlying outstanding options exercisable through 09/01/2031. The filing was signed by an attorney-in-fact on 10/09/2025.